WO2000023567A3 - Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors - Google Patents

Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors Download PDF

Info

Publication number
WO2000023567A3
WO2000023567A3 PCT/EP1999/007741 EP9907741W WO0023567A3 WO 2000023567 A3 WO2000023567 A3 WO 2000023567A3 EP 9907741 W EP9907741 W EP 9907741W WO 0023567 A3 WO0023567 A3 WO 0023567A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
histone deacetylase
renewal
self
hematopoietic stem
Prior art date
Application number
PCT/EP1999/007741
Other languages
French (fr)
Other versions
WO2000023567A2 (en
Inventor
Catherine P Lavau
Judy Carol Young
Beth Louise Hill
Original Assignee
Novartis Ag
Novartis Erfind Verwalt Gmbh
Catherine P Lavau
Judy Carol Young
Beth Louise Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Erfind Verwalt Gmbh, Catherine P Lavau, Judy Carol Young, Beth Louise Hill filed Critical Novartis Ag
Priority to EP99950725A priority Critical patent/EP1129175A2/en
Priority to CA002346152A priority patent/CA2346152A1/en
Priority to AU63393/99A priority patent/AU6339399A/en
Priority to JP2000577279A priority patent/JP2002527101A/en
Publication of WO2000023567A2 publication Critical patent/WO2000023567A2/en
Publication of WO2000023567A3 publication Critical patent/WO2000023567A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of promoting stem cell self-renewal is disclosed which comprises exposing a population of stem cells, particularly hematopoietic stem cells, to an effective dose of a histone deacetylase inhibitor, particularly trichostatin A, trapoxin, or chlamydocin. The invention is also directed to the use of histone deacetylase inhibitors to increase the number of transduced stem cells.
PCT/EP1999/007741 1998-10-16 1999-10-14 Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors WO2000023567A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99950725A EP1129175A2 (en) 1998-10-16 1999-10-14 Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors
CA002346152A CA2346152A1 (en) 1998-10-16 1999-10-14 Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors
AU63393/99A AU6339399A (en) 1998-10-16 1999-10-14 Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors
JP2000577279A JP2002527101A (en) 1998-10-16 1999-10-14 Improved transduction of hematopoietic stem cells and promotion of self-renewal by histone deacetylase inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17363398A 1998-10-16 1998-10-16
US13247699P 1999-05-04 1999-05-04
US09/173,633 1999-05-04
US60/132,476 1999-05-04

Publications (2)

Publication Number Publication Date
WO2000023567A2 WO2000023567A2 (en) 2000-04-27
WO2000023567A3 true WO2000023567A3 (en) 2000-07-27

Family

ID=26830391

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/007741 WO2000023567A2 (en) 1998-10-16 1999-10-14 Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors

Country Status (5)

Country Link
EP (1) EP1129175A2 (en)
JP (1) JP2002527101A (en)
AU (1) AU6339399A (en)
CA (1) CA2346152A1 (en)
WO (1) WO2000023567A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8048999B2 (en) 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
US8058065B2 (en) 2005-12-13 2011-11-15 Kyoto University Oct3/4, Klf4, c-Myc and Sox2 produce induced pluripotent stem cells
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8211697B2 (en) 2007-06-15 2012-07-03 Kyoto University Induced pluripotent stem cells produced using reprogramming factors and a rho kinase inhibitor or a histone deacetylase inhibitor
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
US9499797B2 (en) 2008-05-02 2016-11-22 Kyoto University Method of making induced pluripotent stem cells

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032669A (en) * 1990-05-01 1991-07-16 University Of Massachusetts At Amherst Liquid crystalline polyesters formed by reaction of bis(hydroxyalkoxy) biphenyls with terephthaloyl chloride
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
DE10162080A1 (en) * 2001-12-10 2003-06-26 Albrecht Mueller Process for the production of stem cells with increased development potential
AU2003220119A1 (en) 2002-03-07 2003-09-22 University Of Delaware Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
DE602004031283D1 (en) * 2004-05-05 2011-03-17 Zorica Becker-Kojic Use of glycoprotein ACA antibodies to obtain or maintain pluripotent non-embryonic stem cells
EP1824965B1 (en) * 2004-10-27 2011-10-05 Vrije Universiteit Brussel Hepatic differentiation of stem cells
WO2012046727A1 (en) 2010-10-05 2012-04-12 タカラバイオ株式会社 Method for producing virus vector
BR112014007782B1 (en) 2011-09-30 2021-06-01 Bluebird Bio, Inc. METHOD TO INCREASE THE EFFICIENCY OF LENTIVIRAL TRANSDUCTION OF PROGENITOR CELLS OR CD34+ HEMATOPOIETIC STEM CELLS, AS WELL AS THERAPEUTIC USES OF COMPOSITION INCLUDING SUCH CELLS AND PGE2, 16,16-DIMETHYL PGE2 OR ITS ANALOG
US9399780B2 (en) 2012-03-22 2016-07-26 Takara Bio Inc. Method for producing viral vector
WO2013146480A1 (en) * 2012-03-29 2013-10-03 タカラバイオ株式会社 Gene introduction method
JP6551963B2 (en) * 2014-05-14 2019-07-31 国立大学法人京都大学 Method for producing megakaryocyte precursor cells
KR102097191B1 (en) * 2016-11-10 2020-04-06 울산대학교 산학협력단 Composition for enforcing the priming effect of stem cell comprising histone deacetylase inhibitor and priming factors
WO2018088821A1 (en) * 2016-11-10 2018-05-17 울산대학교 산학협력단 Composition for promoting stem cell activity, comprising histone deacetylase inhibitor and priming factor as active ingredients
WO2021207673A1 (en) * 2020-04-09 2021-10-14 The Regents of the University of Colorodo, a body corporate Compositions, methods and uses for production of hematopoietic stem cells (hscs)
WO2021224633A1 (en) 2020-05-06 2021-11-11 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627487A2 (en) * 1993-05-24 1994-12-07 Immunex Corporation Ligands for FLT3 receptors
WO1997016535A2 (en) * 1995-10-30 1997-05-09 Novartis Ag METHODS FOR USE OF Mpl LIGANDS WITH PRIMITIVE HUMAN STEM CELLS
EP0827743A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone decarboxylase inhibitors for treating fibrosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627487A2 (en) * 1993-05-24 1994-12-07 Immunex Corporation Ligands for FLT3 receptors
WO1997016535A2 (en) * 1995-10-30 1997-05-09 Novartis Ag METHODS FOR USE OF Mpl LIGANDS WITH PRIMITIVE HUMAN STEM CELLS
EP0827743A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone decarboxylase inhibitors for treating fibrosis
EP0827742A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAVAU C. ET AL.: "Inhibitors of histone deacetylases promote primitive hematopoietoic cell self-renewal in ex vivo culture", BLOOD, vol. 92, 15 November 1998 (1998-11-15), pages 504a - 505a, XP000904836 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7741494B2 (en) 2005-07-14 2010-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8048999B2 (en) 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
US8058065B2 (en) 2005-12-13 2011-11-15 Kyoto University Oct3/4, Klf4, c-Myc and Sox2 produce induced pluripotent stem cells
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US8211697B2 (en) 2007-06-15 2012-07-03 Kyoto University Induced pluripotent stem cells produced using reprogramming factors and a rho kinase inhibitor or a histone deacetylase inhibitor
US8257941B2 (en) 2007-06-15 2012-09-04 Kyoto University Methods and platforms for drug discovery using induced pluripotent stem cells
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
US9499797B2 (en) 2008-05-02 2016-11-22 Kyoto University Method of making induced pluripotent stem cells

Also Published As

Publication number Publication date
WO2000023567A2 (en) 2000-04-27
AU6339399A (en) 2000-05-08
CA2346152A1 (en) 2000-04-27
EP1129175A2 (en) 2001-09-05
JP2002527101A (en) 2002-08-27

Similar Documents

Publication Publication Date Title
WO2000023567A3 (en) Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors
WO2003006652A3 (en) Inhibition of specific histone deacetylase isoforms
AU2001248701A1 (en) Inhibitors of histone deacetylase
TR200002446T2 (en) Inhibitors of phospholipase enzymes
NO990338L (en) cell adhesion inhibitor
MXPA04002397A (en) Inhibitors of histone deacetylase.
AU2002243402A1 (en) Inhibitors of histone deacetylase
IL148497A0 (en) Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
CA2515338A1 (en) Inhibitors of histone deacetylase
WO2004005513A3 (en) Methods for specifically inhibiting histone deacetylase-7 and 8
DK1233958T3 (en) Inhibitors of histone deacetylase
EP1567142A4 (en) Treatment of lung cells with histone deacetylase inhibitors
TR199902802T2 (en) Probucol monoesters for the treatment of cardiovascular diseases and inflammatory diseases.
WO2000071703A3 (en) Inhibition of histone deacetylase
AU2002341715A1 (en) Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
ID25853A (en) CAUSES OF POTASSIUM CHANNEL
BR0212014A (en) Use of hydroxamic acid derivatives histone deacetylase inhibitors
NO970410D0 (en) Azaaspartic acid analogues as inhibitors of interleukin-1 <beta> converting enzyme
NO20006023D0 (en) Cell adhesion inhibitor as well as pharmaceutical compositions containing it
GB2389365A (en) Methods for specifically inhibiting histone deacetylase-4
WO2003103613A3 (en) Induction of insulin expression
WO2002015921A3 (en) Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
ZA986673B (en) Use of a combination of an inhibitor of converting enzyme and a diuretic for treating microcirculatory disorders
PL343594A1 (en) Certain thiol inhibitors of endothelin-converting enzyme
IL163875A0 (en) Methods, compositions, and kits for enhancing oli gonucleotide mediated nucleic acid sequence alteration using compositions comprising a histone de

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 63393

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999950725

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2346152

Country of ref document: CA

Ref country code: CA

Ref document number: 2346152

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 577279

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999950725

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999950725

Country of ref document: EP